TY - JOUR
T1 - Targeted agents in non-small cell lung cancer therapy
T2 - What is there on the horizon?
AU - Villaflor, Victoria
AU - Salgia, Ravi
PY - 2013/1/1
Y1 - 2013/1/1
N2 - Lung cancer is a heterogeneous group of diseases. There has been much research in lung cancer over the past decade which has advanced our ability to treat these patients with a more personalized approach. The scope of this paper is to review the literature and give a broad understanding of the current molecular targets for which we currently have therapies as well as other targets for which we may soon have therapies. Additionally, we will cover some of the issues of resistance with these targeted therapies. The molecular targets we intend to discuss are epidermal growth factor receptor (EGFR), Vascular endothelial growth factor (VEGF), anaplastic large-cell lymphoma kinase (ALK), KRAS, C-MET/RON, PIK3CA. ROS-1, RET Fibroblast growth factor receptor (FGFR). Ephrins and their receptors, BRAF, and immunotherapies/vaccines. This manuscript only summarizes the work which has been done to date and in no way is meant to be comprehensive.
AB - Lung cancer is a heterogeneous group of diseases. There has been much research in lung cancer over the past decade which has advanced our ability to treat these patients with a more personalized approach. The scope of this paper is to review the literature and give a broad understanding of the current molecular targets for which we currently have therapies as well as other targets for which we may soon have therapies. Additionally, we will cover some of the issues of resistance with these targeted therapies. The molecular targets we intend to discuss are epidermal growth factor receptor (EGFR), Vascular endothelial growth factor (VEGF), anaplastic large-cell lymphoma kinase (ALK), KRAS, C-MET/RON, PIK3CA. ROS-1, RET Fibroblast growth factor receptor (FGFR). Ephrins and their receptors, BRAF, and immunotherapies/vaccines. This manuscript only summarizes the work which has been done to date and in no way is meant to be comprehensive.
KW - Cellular mechanism
KW - HGF
KW - MET
KW - oncogene
KW - receptor tyrosine kinase
KW - targeted cancer therapy
UR - http://www.scopus.com/inward/record.url?scp=84892575530&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84892575530&partnerID=8YFLogxK
U2 - 10.4103/1477-3163.109253
DO - 10.4103/1477-3163.109253
M3 - Article
C2 - 23599689
AN - SCOPUS:84892575530
SN - 0974-6773
VL - 12
JO - Journal of Carcinogenesis
JF - Journal of Carcinogenesis
M1 - 109253
ER -
